Nataliya P. Buxbaum
Assistant Clinical Investigator
Experimental Transplantation and Immunology Branch, CCR
National Cancer Institute
United States of America
Dr. Buxbaum first came to the NIH as a Howard Hughes Medical Institute (HHMI) research scholar in 2002. She graduated from Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ in 2005 and completed her residency in Pediatrics at Columbia Presbyterian, Children’s Hospital of New York in 2008. She then trained in Pediatric Hematology-Oncology through the Johns Hopkins and National Cancer Institute (NCI) combined fellowship. Dr. Buxbaum is board certified in Pediatrics (2009) and Pediatric Hematology Oncology (2013) and currently serves as an Assistant Clinical Investigator in the Experimental Transplantation and Immunology Branch, NCI. Dr. Buxbaum is a bone marrow transplant (BMT) physician-scientist studying immune-mediated barriers to successful BMT. Dr. Buxbaum’s laboratory and clinical investigations are centered on chronic graft-versus-host disease (cGVHD), which occurs when the immune cells of the donor recognize the organs of the recipient as foreign with resultant damage to these tissues. An increasing number of BMT patients are affected by cGVHD, hence there is an increased need for new and effective treatments for this disease.
1) Chronic graft-versus-host disease (cGVHD), 2) Bone marrow transplantation (BMT), 3) Pediatric cancer, 4) T cell subsets, 5) In vivo cell kinetics, 6) Stable water isotopes, 7) Understanding the biology of cGVHD through the use of pre-clinical models and evaluating pediatric patients on the Natural History of cGVHD study at the NCI.